Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-803 + PD-L1 t-haNK
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravesical, Subcutaneous
01
Overview
N-803 + PD-L1 t-haNK is a combination immunotherapy regimen consisting of N-803 (Anktiva), an interleukin-15 (IL-15) superagonist that enhances natural killer (NK) cells, CD4+ T cells, cytotoxic CD8+ T cells, and memory T-cell activity, combined with PD-L1 t-haNK (PD-L1-targeted high-affinity NK) cells. This combination is designed to overcome immunosuppressive tumor microenvironments by enhancing immune system activation of both NK and T-cells. The PD-L1 t-haNK component consists of modified immune cells that target PD-L1 on tumors without requiring an additional PD-L1 checkpoint inhibitor.
- Brand names
- Anktiva + PD-L1 t-haNK
- Other names
- IL-15 superagonist N-803 + PD-L1-targeted high-affinity NK cellsN-803 + PD-L1.t-haNK
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on N-803 + PD-L1 t-haNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-803 + PD-L1 t-haNK.